Corporate GovernanceAug 3, 2026, 08:03 AM
Anavex Nominates New Directors, Urges Vote Against Activist Investor
AI Summary
Anavex Life Sciences Corp. announced the nomination of two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, as part of a refreshed Board slate for the 2026 Annual Meeting. The company also urged stockholders to reject an attempt by PVG Asset Management Corporation and Patrick S. Adams to gain control, citing PVG's insufficient proxy statement and small ownership stake. Anavex highlighted its focus on advancing its lead candidate, blarcamesine, and the appointment of Dr. Terrie Kellmeyer as interim CEO.
Key Highlights
- Anavex nominated two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz.
- The refreshed Board slate includes Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, and Dr. Claus van der Velden.
- Former CEO Dr. Christopher Missling and Dr. Steffen Thomas were not renominated for the Board.
- The company urged stockholders to reject PVG Asset Management Corporation's attempt to acquire control.
- PVG Asset Management and Patrick S. Adams own 0.35% of Anavex's outstanding shares.
- Dr. Terrie Kellmeyer was appointed interim CEO following the termination of former CEO Missling.
- The company's strategy focuses on blarcamesine for Alzheimer's, Rett syndrome, and Fragile X syndrome.
Price Impact
More from AVXL